Although this is a related party transaction, UBS believes that it will have a positive read-through for BHEL as it is the first commercial use of the company’s proprietary technology, taking the company towards the execution stage from R&D.
Although this is a related party transaction, UBS believes that it will have a positive read-through for BHEL as it is the first commercial use of the company’s proprietary technology, taking the company towards the execution stage from R&D.